shutterstock_44

Airsonett TLA has extensive clinical documentation and is reviewed and recommended by several medical agencies. Please contact us to download further literature or to book a meeting.

Asthma
  • 2023
    • Swedish Medical Products Agency (MPO)

      reviews the guidelines and still recommends TLA as an add-on treatment for Asthma

  • 2022
    • Lawton Retrospective data
      • 12 children (age 6-19)
      • ACT significant improvement
      • TLA treatment may have potential as an add-on, non-pharmacological therapy in selected children and young patients with poorly controlled asthma
    • Chauhan
      • 226 patients
      • Post hoc Kapoor
      • Exacerbations p = 0.083 (33%)
      • QoL p = 0.034
  • 2021
    • Chauhan
      • 179 patients (age 7-75)
      • Meta-analysis Boyle/ Kapoor
      • 52 weeks
      • Exacerbations p = 0.015
      • QoL p = 0.04
    • Miller
      • Health economy Chauhan
      • TLA Cost-effective
      • Well below NICE ICER per QALY threshold (£20K)
      • No biologics has achieved ICER per QALY below $150,000
  • 2020
    • Boven
      • A meta-analysis of baseline characteristics in trials on mite allergen avoidance in
        asthmatics.
      • Statistically significant mean differences in the AQLQ scores and FeNO levels in patients with mild to moderate asthma at baseline.
    • Warner
      • Allergy prevention article
      • TLA treatment showing improvement in QoL and airway inflammation as in FeNO in severe asthma
  • 2019
    • Bjermer
      • 312 patients (7-70)
      • Pivotal within Boyle study
      • 52 weeks
      • 87 patients Time-to-onset QoL 3 months
        p = 0.009
      • 7 patients Time-to-onset Sleep 1 month
        p = 0.037
    • Kapoor
      • 240 patients (age 16-75)
      • RCT
      • 52 weeks
      • Exacerbations
      • Inconclusive, under powered
  • 2018
    • Gupta
      • Refers Boyle et al
      • Significant improvement in QoL
      • Significantly decreased FeNO
      • Importantly, there was a progressively greater significance of difference as the severity of asthma increased.
    • Swedish Medical Products Agency (MPO)

      Renewed recommendation

    • BLFA guidelines (Swedish Paediatricians’ Association) guidelines

      Also recommended for Atopic Dermatitis: “Treatment with Airsonett can be particularly valuable in the combination of severe asthma and severe eczema, as the treatment affects both conditions favourably.”

  • 2017
    • Warner Publication
      • TLA have demonstrated significant improvements in QoL and reduction in FeNO
      • Significant reduction of severe exacerbation in patient with worse disease
      • TLA treatment below the NICE threshold for the ICER per QALY
    • Wang
      • 23 patients
      • RCT, withdrawal of Omalizumab
      • 48 weeks
      • Exacerbations p = 0.001
    • BLFA (Swedish Paediatricians’ Association) guidelines

      recommends TLA for “patients with verified perennial airway allergy and uncontrolled asthma despite drug treatment step 4”

  • 2016
    • Spilak
      • Climate chamber with manikin
      • TLA vs. Air cleaner
      • ≥0.5 µm; particle exposure > 99.5%, p < 0.001
      • 100-fold vs. Air cleaner, p < 0.001
    • Gore RB
      • 12 children (age 8-15)
      • Severe atopic eczema
      • Children slept under device OFF two nights and ON two nights.
      • ≥0.5 µm; particle exposure > 99.5% p < 0.001
    • Brazier
      • Health economy Boyle/Schauer
      • TLA Cost-effective
      • Well below NICE ICER per QALY threshold (£20K)
  • 2015
    • Gore RB
      • 5 subjects
      • Allergen-rich experimental environment incl. cat allergen
      • ≥0.5 µm; particle exposure reduction > 99.5%, p < 0.001
      • Cat allergen exposure reduction p = 0.043
    • Schauer
      • 30 patients (age 8-70 )
      • Observation
      • 52 weeks
      • Exacerbations p < 0.0001
      • ACT < 0.0001
    • Swedish Medical Products Agency recommendation

      Add-on treatment asthma (MPO)

    • The Swedish Dental and Pharmaceutical Benefits Agency (TLV)

      considers treatment with TLA to be cost-effective given the data available, provided that the patient corresponds to the indication.

  • 2014
    • Bakshi
      • 6 subjects
      • 1 week TLA-treatment in inner city environment
      • Nano particle exposure reduction >99.5%,
      • p = < 0.001
  • 2012
    • Boyle
      • 312 patients (age 7-70)
      • RCT
      • 52 weeks
      • QoL p = 0.02
      • poorly ctrl. p < 0.001
      • FeNO p = 0.03 high baseline p = 0.001
      • Cat-specific IgE p = 0.005
    • HO
      • 14 patients (adults)
      • RCT, cross-over
      • NRQLQ p = 0.013
      • Decrease in IFN-gamma p = 0.028 (nasal secretions)
  • 2011
    • Moffat
      • 53 patients (age 8-16)
      • RCT within Boyle study
      • 52 weeks
      • RQLQ sleep p = 0.019
      • Significant reduction in PNIF
  • 2010
    • Ragazzo
      • 9 patients (age 7-12)
      • Proof of concept
      • Patient living in the alps randomized to TLA or control, when moving back home.
      • Showed reduction in inflammation markers as FeNO and sputum EOS
  • 2009
    • Pedroletti
      • 22 patients (age 12-33)
      • RCT, cross-over
      • 22 weeks
      • QoL p < 0.05
      • FeNO < 0.05
    • Brodtkorb
      • Health Economy Pedroletti study
      • TLA Cost-effective
      • Well below NICE ICER per QALY threshold (€30K)
Atopic dermatitis
  • 2023
    • Gore (Ongoing)
      • 96 patients (children)
      • RCT, single centre Imperial College London UK
      • 12weeks
      • EASI
      • SCORAD, DLQI, IGE/PGA
  • 2021
    • Traidl
      • 10 patients (age >18)
      • Observational, Proof of concept Hannover University
      • 12 weeks and follow up 9 months
      • SCORAD p = 0.037, EASI p = 0.038
      • DLQI p = 0.001
      • IL9 p = 0.0001
      • First study to show invitro data
  • 2018
    • Gore
      • 15 patients (age 2-16)
      • Open label, Proof of concept Imperial Collage London UK
      • 52 weeks
      • SCORAD p = 0.015, IGA p = 0.001
      • FDLQI p = 0.032
    • Theodosiou publication
      • 1 patient
      • Patient cases
      • Significant improvement in SCORAD, IGA, DLQI
    • BLFA (Swedish Paediatricians’ Association) guidelines

      “Treatment with Airsonett can be particularly valuable in the combination of severe asthma and severe eczema, as the treatment affects both conditions favourably.”

  • 2014
    • Leitao/Gore
      • 6 patients
      • Proof of Concept
      • 52 weeks
      • QoL and SCORAD improved
      • Reduction of aeroallergens exposure by TLA treatment can improve disease severity and quality of life in children with severe atopic eczema.
  • 2012
    • Söderman
      • 8 patients (age 5-16)
      • Case report, Multi centre
      • TLA may be an alternative for subjects with severe perennial allergen-induced AD.